Journal of Hematology & Oncology

official impact factor 2.93

Open Access Highly Access

From basic research to clinical development of MEK1/2 inhibitors for cancer therapy

Christophe Frémin and Sylvain Meloche*

Journal of Hematology & Oncology 2010, 3:8 doi:10.1186/1756-8722-3-8

Accesses  

  • Last 30 days: 216 accesses
  • Last 365 days: 3203 accesses
  • All time: 7097 accesses

Cited by